Categories
Corporate

Emami to take over Axiom Ayurveda in ₹200 cr deal

Emami Ltd, the Kolkata-based FMCG company, has announced it will acquire the remaining 73.5% stake in Axiom Ayurveda Pvt Ltd for up to ₹200 crore, making the ayurveda-focused company its wholly owned subsidiary. Earlier, Emami had acquired a 26.5% stake in Axiom, and this move completes its takeover, aiming to expand its presence in the fast-growing health and wellness segment.

The board of Emami approved the acquisition on March 31, 2026, and a definitive agreement was signed on April 1. The deal reflects Emami’s strategy to diversify into emerging consumer categories, particularly products with natural and functional benefits.

Axiom Ayurveda is known for its aloe vera-based beverages, including the popular “AloFrut” brand, which blends aloe pulp with fruit juices. In addition to aloe vera drinks, the company produces ayurvedic juices, energy drinks, mocktails, and some personal care products. These offerings account for around 15–20% of its branded business.

In the financial year 2024–25, Axiom reported a consolidated turnover of roughly ₹107 crore. Following the acquisition, Emami expects the business to grow substantially, with projections suggesting revenue could reach around ₹180 crore in the current fiscal year.

Industry analysts say the acquisition will allow Emami to leverage Axiom’s existing product portfolio, distribution network, and brand recognition. The company aims to accelerate innovation, expand market reach, and capitalize on the increasing demand for healthier, functional beverages in India.

This acquisition underscores Emami’s broader strategy to strengthen its foothold in wellness-driven segments beyond its traditional personal care business. By fully integrating Axiom Ayurveda, Emami is positioned to tap into the growing consumer preference for natural, nutritious, and functional products, particularly in the beverage space.

Also Read: Emirates NBD gets RBI nod to acquire RBL Bank

Categories
Corporate

Emami shares rise 5% as brokers expect strong FY26 growth

Emami Ltd’s shares jumped about 5% on Thursday, rising from ₹514 to ₹538 on the NSE, after brokers turned optimistic about the company’s performance in the second half of fiscal 2026.

Brokers like Nuvama Institutional Equities said past slowdowns due to GST and product changes are over. With inventories back to normal, Emami is likely to see double-digit revenue growth. Its international business, which makes up around 18% of sales, is also expected to grow. Core product categories, which form 70% of sales, are forecasted to grow 5–7% annually, and Emami aims to increase direct-to-consumer sales from 6% today to 20% in the next 3–4 years.

Goldman Sachs has a ‘Buy’ rating with a target price of ₹825, expecting strong earnings over the next year, supported by stable demand, good winter season sales, and improved operations.

However, brokers warned of risks like competition in niche products, leadership changes, and seasonal demand fluctuations, which could affect earnings.

Investors see potential for gains if sales improve as expected, but should watch the coming quarters closely due to seasonal and market risks.

Also Read: ICICI Prudential AMC gets SEBI nod for $12 billion IPO